PathAI logo

Steatosis reduction assessed by MRI-PDFF was consistent with ML evaluation in patients with NASH cirrhosis

AASLD 2022

Study Background

• Liver biopsies evaluated by hepatopathologists are a key method for assessing treatment response in trials of non-alcoholic steatohepatitis (NASH).

– Artificial intelligence has shown promise in supporting liver biopsy assessment.

• Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) is a non-invasive imaging technique that can assess total liver fat content.

• This post hoc analysis aimed to compare steatosis assessment by histologic evaluation (pathologist or PathAI’s machine learning [ML] models) and by MRI-PDFF.

– The analysis used data from a randomized, double-blind, placebo-controlled phase 2 trial investigating once-weekly subcutaneous semaglutide 2.4 mg in patients with NASH and compensated cirrhosis.
View Poster


Loomba et al.